CN201135707Y - A device for treating prostatic disease and females urethra syndrome - Google Patents
A device for treating prostatic disease and females urethra syndrome Download PDFInfo
- Publication number
- CN201135707Y CN201135707Y CNU2007200101188U CN200720010118U CN201135707Y CN 201135707 Y CN201135707 Y CN 201135707Y CN U2007200101188 U CNU2007200101188 U CN U2007200101188U CN 200720010118 U CN200720010118 U CN 200720010118U CN 201135707 Y CN201135707 Y CN 201135707Y
- Authority
- CN
- China
- Prior art keywords
- urethra
- light
- conduit
- light source
- prostate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Radiation-Therapy Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The utility model relates to a therapy device for prostate disease or female urethra syndrome. A therapeutic catheter inside the urethra adopts a double-vesicle catheter structure, a light source emitting electrode is installed between the two air vesicles of the catheter, namely a location air vesicle and an obturation air vesicle, and a principal machine for providing a therapeutic light source is connected with the light source emitting electrode through a transmission line; a temperature controller is connected with a temperature sensing device arranged on the light source emitting electrode and controls the temperature of the light source emitting electrode to be 41+-1 DEG C. The therapy device is characterized in that firstly, the light, the heat and the medicine compound therapy are applied in the prostate (male) and the posterior urethra (female) region through the urethra, simultaneously because of an electric heating function, the permeation and the absorption capacity of regional medication perfusing medicine are enhanced, thus, the therapeutic purpose of prostatitis or female urethra syndrome is achieved. Secondly, photosensitizer is perfused in the prostate through the urethra, and the prostate is irradiated by adding a specific wavelength, and thereby, the therapy of the prostate disease can be realized through performing the photodynamic therapeutics of photosensitizer to regions.
Description
Technical field
This utility model relates to a kind of prostatosis and female urethra symptom group therapy equipment, be to adopt the partial light of per urethra, heat, recurrence due to taking drug to close the device that mode is treated male prostatitis, prostatic hyperplasia, carcinoma of prostate and female urethra syndrome, belong to technical field of medical instruments.
Background technology
(1) chronic prostatitis is male's a kind of commonly encountered diseases and a frequently-occurring disease, according to statistics, in the 25-40 male in year, there is the people of 30%-40% to suffer from various degree chronic prostatitis, owing to what at present the reason of its morbidity is also understood is not fully aware of, add its more special anatomical structure and the multiple frequent many-sided reasons such as crowd of sexual activity of being born in, make very difficult its treatment.Usually can see prostatitic patient in the life and repeatedly cure, all the situation that can not effect a radical cure.Present Therapeutic Method mainly contains: antibiotic medicine treatment and physiotherapy.Because the medicine that the special anatomical structure of prostate, oral or injection enter in the blood is difficult to go into prostatic fluid from the blood plasma disperse, so how undesirable therapeutic effect is.Physiotherapy is to use the electromagnetic wave or the light wave of various different frequencies, and commonly used has: ultrasound wave, shortwave, ultrashort wave, microwave, HONGGUANG and infrared light.Since above various physiotherapys all be act on external perineal position or hypogastric region indirect to the prostate radiation, be difficult to reach effective therapeutic purposes.
(2) female urethra symptom group is the commonly encountered diseases of Urology Surgery and department of obstetrics and gynecology outpatient service, it is the syndrome of one group of frequent micturition, urgent micturition, dysurea, hypogastric region discomfort, can betide the women at any age, and is the highest to give birth to back middle-aged women sickness rate especially, can show effect obstinate repeatedly.Also there is the body of gland that is equivalent to male prostate at women's urethra rear portion on the anatomy, and these bodies of gland also are subjected to endocrine the influence and control simultaneously in embryo's period and male prostate homology.If chronic inflammatory disease or nodositas tumor sample hypertrophy take place, cause bladder neck narrow even block, then can produce a series of symptoms based on the discomfort of urinating.The cause of disease of urethra symptom group is also not fully aware of, and is also difficult in the treatment.The main at present method of using has antibiotic therapy, urethral dilatation or physical therapy.Identical with prostate treatment and since used various physiotherapys all be act on external perineal position or hypogastric region indirect to back urethra radiation, be difficult to reach effective therapeutic purposes.
(3) prostatic hyperplasia is the commonly encountered diseases of elderly men, and carcinoma of prostate also is a kind of commonly encountered diseases of male.Two sick sickness rate are all very high.The prostate of ill hypertrophy can be oppressed the back urethra and be caused urinary tract obstruction and cause patient urinates not smooth, and easy secondary lithangiuria, infects, and can cause renal failure when serious.It is operation or TUR that present prostatic hyperplasia is identified effective Therapeutic Method.Operation or TUR, patient need be in hospital, and anesthesia and blood transfusion are bigger to patient's strike.Photodynamic therapy is the new method of the treatment tumor of rising in recent years, its treatment principle is that patient accepted behind injection or the oral photosensitizer in the regular hour, tumor or outgrowth pathological tissues contain the photosensitizer of high energy degree, use the light source irradiation tumor or the pathological tissues of specific wavelength this moment, and the back produces a kind of strong oxidizer kill tumor or pathological tissues but the photosensitizer in tumor or the pathological tissues is excited.This therapy has high specificity, curative effect height, cost is low and do not have advantages such as wound.Various tumors and improper proliferative lesion have been widely used in treating at home and abroad.But after the disadvantage of photodynamic therapy was photosensitizer oral administration or quiet notes administration, whole body is respectively organized all distribution, is easy to cause photoallergic dermatitis behind contact patients daylight or the light, and severe patient can cause corneal injury.Therefore, the patient who accepts photodynamic therapy treatment needs lucifuge a couple of days to several weeks, and is very inconvenient.
The utility model content
The purpose of this utility model is to provide a kind of prostatosis and female urethra symptom group therapy equipment at the problem of above-mentioned background technology () and (two) existence.This device is that the visible or infrared light light emitted utmost point that can launch certain wavelength is installed on the special two capsule urethra inner catheters, can be by positioning gasbag with light emitted utmost point per urethra accurate in locating urethra area behind male prostate position or women, antibacterials can be through this catheter perfusion urethra part behind male prostate or the women, the endo-urethral drug level of local prostate or back is obviously increased, overcome oral administration or injectable drug and be difficult to arrive the endo-urethral shortcoming of prostate or back.The particularly infrared light wavelength of visible light is longer, tissue is had very strong penetration power and easily is organized absorb and the generation heat effect, promotes local blood circulation and metabolism.The heat effect that light produces tissue, antiinflammation and promotion regeneration are affirmed by clinical.To improve effect remarkable, obvious with improving blood flow especially to microcirculatory in the near-infrared microirradiation.Show as irradiation back capillary blood flow and speed up, the erythrocyte aggregation phenomenon reduces, and the venous congestion phenomenon alleviates or disappears under the nipple, thereby improves nutrition, metabolism and the reparation of body tissue.Because this utility model is introduced directly into prostate (male) or back urethra (women) partial radiation with the phototherapy per urethra, its therapeutic effect is far longer than extracorporeal irradiation obviously improves curative effect.Because the heat effect of light radiation, prostate or the back partial temperature of urethra raise, strengthened partial drug osmotic, improved the absorption of prostate (male) or back urethra (women) tissue, further improved the therapeutic effect of prostatitis (male) or urethral syndrome (women) medicine.
Another purpose of the present utility model is to provide at the problem that exists in the above-mentioned background technology (three) a kind of purposes of described therapy equipment, and described therapy equipment is used for the photodynamic therapy treatment of per urethra topical to prostatic hyperplasia or carcinoma of prostate.Described photosensitizer can be through two capsule urethra internal therapy catheter perfusions to the prostate part, enters into prostate essence and is absorbed by prostate through ducts of prostate gland is reverse, forms very high concentration in prostata tissue.In reasonable time,, excite the photosensitizer in the prostata tissue, kill and wound partial prostata tissue and reach prostatic hyperplasia and treatment of prostate cancer by being installed in the light that the light emitted utmost point between treatment conduit two air bags sends specific wavelength.
The purpose of this utility model is achieved through the following technical solutions:
This utility model prostatosis and female urethra symptom group therapy equipment are formed by main frame, temperature control instrument, drug infusion device, the urethra internal therapy conduit for the treatment of light source being provided and being arranged on the supravasal light emitted utmost point; Urethra internal therapy conduit is two capsule catheter structures, and the light emitted utmost point is installed between the two air bag positioning gasbags and closed airbag of conduit, provides the main frame of treatment light source to be connected with the light emitted utmost point by transmission line; Temperature control instrument be arranged on that temperature sensing device that light emitted extremely goes up is connected and the temperature of controlling the light emitted utmost point is 41 ± 1C °.
Described the main frame of treatment light source is provided is power supply formula main frame or light-source type main frame, and power supply formula main frame provides the visible or infrared light light source by lighting transistor, adopts alternating current power supply or DC power supply mode; The light-source type main frame provides light source by laser, and the various visible light LASER Light Sources of wavelength more than 500nm that provide are provided.
Described transmission line is power lead or optical fibers, and the power supply of lighting transistor is connected with the light emitted utmost point through power lead, and the emission source of laser is connected with the light emitted utmost point through optical fibers.
The length overall of described urethra internal therapy conduit is 400-450mm, and external diameter is 3.3-7mm, and the two air bag positioning gasbags of conduit and the spacing of closed airbag are the 40-60 millimeter; Conduit comprises that several medicine permeating holes between two air bags are communicated with the perfusion hole through the perfusion chamber, positioning gasbag is communicated with the positioning gasbag injecting hole that check valve is housed through the positioning gasbag inflatable chamber, closed airbag is communicated with the closed airbag injecting hole that check valve is housed through the closed airbag inflatable chamber, and the urethral catheterization aperture urethral catheterization chamber of catheter proximal end links to each other with urine drainage bag.
This utility model utilizes light (visible or infrared light etc.) per urethra of tool physical effect in prostate-urethra position (male) or back urethra area (women) part to be imposed light, and hot recombination radiation also cooperates topical remedy's perfusion therapy prostatic diseases or female urethra syndrome.
Another purpose of the present utility model is achieved through the following technical solutions:
Described prostatosis and female urethra symptom group therapy equipment are used for local the giving with the photodynamic therapy of photosensitizer of prostate and treat prostatic hyperplasia or carcinoma of prostate, but perfusion hole, perfusion chamber and the medicine permeating hole of photosensitizer per urethra internal therapy conduit are injected into prostate, cooperate the light source irradiation prostate of specific wavelength behind the certain hour at interval, prostatic hyperplasia or carcinoma of prostate are treated through the photodynamic therapy of topical thereby reach.
The beneficial effects of the utility model are:
(1) therapy equipment of the present utility model is applied to prostate (male) and urethra (women) part, back with the phototherapy per urethra, simultaneously because HONGGUANG or infrared ray are darker to penetrating of tissue, be easy to be organized absorption, has very strong local heat effect, blood circulation promoting and metabolism improve sterilizing ability and immunocompetence.Medicine can cooperate optical heat radiation through the treatment catheter perfusion to local, has strengthened the infiltration and the absorbability of regional perfusion's medicine, reaches the Comprehensive Treatment purpose of treatment prostatosis or female urethra symptom group.
(2) utilize therapy equipment of the present utility model, per urethra carries out photodynamic therapy treatment prostatosis in prostate regional perfusion photosensitizer, has avoided the side effect of systemic administration.
Description of drawings
Fig. 1 is a structural representation of the present utility model.
Fig. 2 is a conduit section structure A-A cut-away view of the present utility model.
Fig. 3 is an actual utilization structure view of the present utility model.
Among the figure: 1. main frame, 2. temperature control instrument, 3. urethra internal therapy conduit, 4. the light emitted utmost point, 5. temperature sensing device, 6. transmission line (power lead or optical fibers), 7. positioning gasbag, 8. closed airbag, 9. positioning gasbag inflatable chamber, 10. closed airbag inflatable chamber, 11. the positioning gasbag injecting hole, 12. closed airbag injecting holes, 13. medicine permeating holes, 14. the perfusion chamber, 15. perfusion holes, 16. urine drainage holes, 17. the urethral catheterization chamber, 18. urine drainage bags, 19. drug infusion devices.
The specific embodiment
Describe this utility model in detail below in conjunction with drawings and Examples.
Embodiment 1:
As illustrated in fig. 1 and 2, this utility model therapy equipment comprises main frame 1, temperature control instrument 2, drug infusion device 19, the urethra internal therapy conduit 3 that the treatment light source is provided and is installed in the conduit light emitted utmost point 4.
Provide the main frame 1 of treatment light source can adopt power supply formula main frame or light-source type main frame, wherein: power supply formula main frame provides the visible or infrared light light source by lighting transistor (LED), adopts alternating current power supply or DC power supply; The light-source type main frame provides light source by laser, and the various visible light LASER Light Sources of wavelength more than 500nm that provide are provided.
The two capsule catheter structures that urethra internal therapy conduit 3 is made by transparent material such as silica gel, conduit 3 length overalls are 400-450mm, and external diameter is 3.3-7mm, and two air bags of conduit 3 are that positioning gasbag 7 and closed airbag 8, two air bag spacings are the 40-60 millimeter.The light emitted utmost point 4 is installed between two air bags of conduit, and the medicine permeating hole 13 on the perfusion chamber 14 is opened between two air bags.Local light heat radiation and medicine are filled into prostate (male) or back urethra (women) is realized by conduit 3.The power supply of lighting transistor or the emission source of laser are connected to the light emitted utmost point 4 through power lead or optical fibers 6.Positioning gasbag 7 gas injection capacity are the 4-10 milliliter, communicate with the positioning gasbag injecting hole 11 that check valve is housed through positioning gasbag inflatable chamber 9, are used for location and fixed light source emitter stage 4 in prostatic.Closed airbag 8 gas injections or the water yield are the 1-3 milliliter, communicate with the closed airbag injecting hole 12 that check valve is housed through closed airbag inflatable chamber 10, being used to seal the prostatic urethra position is an isolation lacuna, and the medicine that is filled in this lacuna can be retained and the reverse prostata tissue that penetrates into.Temperature control instrument 2 is connected in temperature sensing device 5 through lead, and temperature sensing device 5 is installed in the light emitted utmost point 4 surfaces, can adopt the thermocouple temperature measurement mode.During treatment, the Temperature Feedback that temperature sensing device 5 is surveyed is to temperature control instrument 2, and temperature controller 2 is being controlled the temperature of the light emitted utmost point 4 at 41 ± 1C °.The urethral catheterization hole 16 of conduit 3 front ends links to each other with urine drainage bag 18 through urethral catheterization chamber 17, is used for drain patient's urine during treatment.
As shown in Figure 3, this utility model therapy equipment is used for the treatment of prostatitis or urethra symptom group: patient is flat to crouch, to treat conduit under the sterile working inserts in the urethra, after the emptying intravesical urine, inject 4-10 milliliter air or saline through positioning gasbag injecting hole 11, make positioning gasbag full, outwards the tractive conduit makes positioning gasbag push down internal urethral orifice, and this moment, the light emitted utmost point 4 and medicine permeating hole 13 were positioned at prostate (man) or urethra (woman) position, back just.Injecting 1～3 ml physiological saline through closed airbag injecting hole 12 makes closed airbag 8 full.At this moment the prostate-urethra position between two air bags becomes a segregate sealing lacuna.Medicine is circulated into prostatic through perfusion hole 15 under the effect of gravity, at this moment, can start shooting to treating with light radiation.
As shown in Figure 3, this utility model therapy equipment is used for that prostate is local to be given and photosensitizer treatment prostatic hyperplasia and carcinoma of prostate: as above-mentioned treatment prostatitis, the treatment conduit inserts urethra, full positioning gasbag and closed airbag, photosensitizer is circulated into prostatic through perfusion hole 15 under the effect of gravity, enter into prostate essence and absorbed by prostate through the prostate glandular tube is reverse again.Between at regular intervals after, photosensitizer forms very high concentration in prostata tissue, start shooting this moment, is sent the light of specific wavelength by the light emitted utmost point 4, excite the photosensitizer in the prostata tissue, kill and wound the prostata tissue in institute's irradiated region and reach prostatic hyperplasia and treatment of prostate cancer.
Claims (4)
1. prostatosis and female urethra symptom group therapy equipment is characterized in that: this therapy equipment is made up of main frame (1), temperature control instrument (2), drug infusion device, urethra internal therapy conduit (3) that the treatment light source is provided and the light emitted utmost point (4) that is arranged on the conduit (3); Urethra internal therapy conduit (3) is two capsule catheter structures, the light emitted utmost point (4) is installed between the two air bag positioning gasbags (7) and closed airbag (8) of conduit (3), provides the main frame (1) of treatment light source to be connected with the light emitted utmost point (4) by transmission line (6); Temperature control instrument (2) is connected with temperature sensing device (5) on being arranged on the light emitted utmost point (4) and the temperature of controlling the light emitted utmost point (4) is 41 ± 1 ℃.
2. prostatosis according to claim 1 and female urethra symptom group therapy equipment, it is characterized in that: described provide the treatment light source main frame (1) be power supply formula main frame or light-source type main frame, power supply formula main frame provides the visible or infrared light light source by lighting transistor, adopts alternating current power supply or DC power supply mode; The light-source type main frame provides light source by laser, and the various visible light LASER Light Sources of wavelength more than 500nm that provide are provided.
3. prostatosis according to claim 1 and female urethra symptom group therapy equipment, it is characterized in that: described transmission line (6) is power lead or optical fibers, the power supply of lighting transistor is connected with the light emitted utmost point (4) through power lead, or the emission source of laser is connected with the light emitted utmost point (4) through optical fibers.
4. prostatosis according to claim 1 and female urethra symptom group therapy equipment, it is characterized in that: the length overall of described urethra internal therapy conduit (3) is 400-450mm, external diameter is 3.3-7mm, and the two air bag positioning gasbags (7) of conduit (3) and the spacing of closed airbag (8) are the 40-60 millimeter; Conduit (3) comprises that several medicine permeating holes (13) between two air bags are communicated with perfusion hole (15) through perfusion chamber (14), positioning gasbag (7) is communicated with the positioning gasbag injecting hole (11) that check valve is housed through positioning gasbag inflatable chamber (9), closed airbag (8) is communicated with the closed airbag injecting hole (12) that check valve is housed through closed airbag inflatable chamber (10), and the urethral catheterization hole (16) of conduit (3) front end links to each other with urine drainage bag (18) through urethral catheterization chamber (17).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2007200101188U CN201135707Y (en) | 2007-01-15 | 2007-01-15 | A device for treating prostatic disease and females urethra syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2007200101188U CN201135707Y (en) | 2007-01-15 | 2007-01-15 | A device for treating prostatic disease and females urethra syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN201135707Y true CN201135707Y (en) | 2008-10-22 |
Family
ID=40036395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNU2007200101188U Expired - Fee Related CN201135707Y (en) | 2007-01-15 | 2007-01-15 | A device for treating prostatic disease and females urethra syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN201135707Y (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100998912B (en) * | 2007-01-15 | 2010-04-14 | 郑成福 | Therapeutic device for prostate disease and female urethra symptom group |
| CN105327456A (en) * | 2014-08-12 | 2016-02-17 | 明基三丰医疗器材股份有限公司 | Infrared ray irradiation device for urinary tract |
| CN108938137A (en) * | 2018-06-25 | 2018-12-07 | 哈尔滨医科大学 | Transurethral bladder communication apparatus |
| US10357661B2 (en) | 2011-09-30 | 2019-07-23 | Percuvision, Llc | Medical device and method for internal healing and antimicrobial purposes |
| CN112007261A (en) * | 2020-09-10 | 2020-12-01 | 杨志巧 | Bladder medicine feeder for obstetrics and gynecology department |
| WO2021160751A1 (en) * | 2020-02-14 | 2021-08-19 | Albert-Ludwigs-Universität Freiburg | Catheter with antimicrobial action for the prevention of adherence |
-
2007
- 2007-01-15 CN CNU2007200101188U patent/CN201135707Y/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100998912B (en) * | 2007-01-15 | 2010-04-14 | 郑成福 | Therapeutic device for prostate disease and female urethra symptom group |
| US10357661B2 (en) | 2011-09-30 | 2019-07-23 | Percuvision, Llc | Medical device and method for internal healing and antimicrobial purposes |
| CN105327456A (en) * | 2014-08-12 | 2016-02-17 | 明基三丰医疗器材股份有限公司 | Infrared ray irradiation device for urinary tract |
| CN108938137A (en) * | 2018-06-25 | 2018-12-07 | 哈尔滨医科大学 | Transurethral bladder communication apparatus |
| WO2021160751A1 (en) * | 2020-02-14 | 2021-08-19 | Albert-Ludwigs-Universität Freiburg | Catheter with antimicrobial action for the prevention of adherence |
| CN112007261A (en) * | 2020-09-10 | 2020-12-01 | 杨志巧 | Bladder medicine feeder for obstetrics and gynecology department |
| CN112007261B (en) * | 2020-09-10 | 2022-07-15 | 杨志巧 | Bladder medicine feeder for obstetrics and gynecology department |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10307610B2 (en) | Method and apparatus for light-activated drug therapy | |
| KR102666387B1 (en) | Device for photodynamic therapy | |
| CN201135707Y (en) | A device for treating prostatic disease and females urethra syndrome | |
| Taber et al. | Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study. | |
| Delaney et al. | Phase I study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors | |
| Chen et al. | Tumor oxygenation changes post‐photodynamic therapy | |
| Marcus | Photodynamic therapy of human cancer: clinical status, potential, and needs | |
| CN103405769A (en) | Application of photosensitizer to preparation of virus inactivated medicines for treating diseases | |
| CN100998912B (en) | Therapeutic device for prostate disease and female urethra symptom group | |
| CN2912675Y (en) | Two-chamber water capsule type esophagus radioactive source application equipment | |
| CN107174726A (en) | A kind of implanted chemotherapy infusion system for being used to treat carcinoma of urinary bladder | |
| CN100496428C (en) | Apparatus for treating prostate diseases, and its making method | |
| Rich et al. | Preoperative combined modality therapy for pancreatic cancer | |
| CN2189938Y (en) | Catheter for combined treatment of prostatitis | |
| CN208641511U (en) | A kind of Modulatory character three-cavity structure bile duct brachytherapy drainage tube | |
| Eckstein | Cutaneous ureterostomy | |
| Krasner et al. | Photodynamic therapy of tumours in gastroenterology—a review | |
| Lawton et al. | Simultaneous high-energy irradiation and chemotherapy | |
| CN207562228U (en) | Encephalic Radiotherapy chemotherapy one two-chamber primary and secondary capsule | |
| CN201759977U (en) | Double-balloon and tetra-chamber local administration catheter | |
| Jacobs et al. | Pathologic effects of pre-cystectomy therapy with combination intra-arterial doxorubicin hydrochloride and local bladder hyperthermia for bladder cancer | |
| CN206138559U (en) | Prostate ozone pouring guide pipe | |
| CN2624843Y (en) | No-wound insertion type self-ablating bistoury for treating prostate | |
| Ji et al. | Minimally invasive intervention of obstructive jaundice in pancreatic cancer | |
| CN215608200U (en) | Disposable bladder fills uses simple and easy type single chamber ureter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081022 Termination date: 20110115 |